The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma
Open accessAbstract
Background/aims: To investigate the prognostic values of putative hepatic stem/progenitor cell (HSC/HPC) biomarkers in patients with hepatocellular carcinoma (HCC). Methods: Fourteen biomarkers related to HSCs/HPCs or tumour angiogenesis were assessed by qRT-PCR and then validated by tissue microarrays (TMAs) in three independent cohorts of patients with HCC undergoing curative resection (n=67, 314 and 73). Results: Most of the biomarkers were found to be overexpressed in patients with recurrent HCC by quantitative reverse transcription–PCR (qRT–PCR). The HSC/HPC biomarkers cytokeratin 19, ATP-binding cassette subfamily G member 2 (ABCG2), CD133, Nestin and CD44, and the markers of angiogenesis microvessel density (MVD, determined by CD34 immunostaining), vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) were confirmed as significant predictors for overall survival (OS) and/or relapse-free survival (RFS) in TMA analysis. As compared with the low HSC/HPC profile group, patients with a high HSC/HPC profile who had higher VEGF levels (p=0.012) and MVD (p=0.030) in tumours had significantly lower OS and RFS (p<0.0001). Based on Cox regression, a simplified model including CD133, CD44, Nestin and MVD was constructed and confirmed as an independent predictor for OS (p<0.0001) and RFS (p<0.0001), regardless of α-fetoprotein level, tumour stage and recurrence time (p<0.0001 for all). Conclusion: High expression levels of HSC/HPC biomarkers are related to tumour angiogenesis and poor prognosis of HCC. The simplified model based on the HSC/HPC and tumour angiogenesis profile can be used to classify patients with HCC with a high risk of tumour recurrence after surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Cited by
Cancer stem cells in the development of liver cancer
Yamashita, T., & Wang, X. W. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66024 · Cited by 525
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K.-W., Guan, X.-Y., & Ma, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 460
Sun, Y.-F., Xu, Y., Yang, X.-R., Guo, W., Zhang, X., Qiu, S.-J., Shi, R.-Y., Hu, B., Zhou, J., & Fan, J. (2013) · Hepatology · doi:10.1002/hep.26151 · Cited by 404
Self-citationKim, H., Choi, G. H., Na, D. C., Ahn, E. Y., Kim, G. I., Lee, J. E., Cho, J. Y., Yoo, J. E., Choi, J. S., & Park, Y. N. (2011) · Hepatology · doi:10.1002/hep.24559 · Cited by 341
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338
“Many studies have shown that the high level of CD133 predicts a poor prognosis in human HCC patients, is associated with lower survival rate, and also positively correlates with a high level of microvessel density and CD34C cells infiltration in the tumor bed.(18,19) On the other hand, CD133 is currently the most matu…”
BackgroundGrosse‐Gehling, P., Fargeas, C. A., Dittfeld, C., Garbe, Y., Alison, M. R., Corbeil, D., & Kunz‐Schughart, L. A. (2013) · The Journal of Pathology · doi:10.1002/path.4086 · Cited by 301
Intratumor Heterogeneity in Hepatocellular Carcinoma
Friemel, J., Rechsteiner, M., Frick, L., Böhm, F., Struckmann, K., Egger, M., Moch, H., Heikenwalder, M., & Weber, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0122 · Cited by 296
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis
Hernandez, C., Huebener, P., Pradere, J.-P., Antoine, D. J., Friedman, R. A., & Schwabe, R. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci91786 · Cited by 110
Pusterla, T., Nèmeth, J., Stein, I., Wiechert, L., Knigin, D., Marhenke, S., Longerich, T., Kumar, V., Arnold, B., Vogel, A., et al. (2013) · Hepatology · doi:10.1002/hep.26395 · Cited by 97
STAT3 in hepatocellular carcinoma: new perspectives
Svinka, J., Mikulits, W., & Eferl, R. (2014) · Hepatic Oncology · doi:10.2217/hep.13.7 · Cited by 63
Miao, S., Qiu, T., Zhao, Y., Wang, H., Sun, X., Wang, Y., Xuan, Y., Qin, Y., & Jiao, W. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12797 · Cited by 28
Nestin-Expressing Cells in the Lung: The Bad and the Good Parts
Jaramillo-Rangel, G., Chávez-Briones, M.-D.-L., Ancer-Arellano, A., & Ortega-Martínez, M. (2021) · Cells · doi:10.3390/cells10123413 · Cited by 25
Metadata
- Authors
- Yang, X.-R., Xu, Y., Yu, B., Zhou, J., Qiu, S.-J., Shi, G.-M., Zhang, B.-H., Wu, W.-Z., Shi, Y.-H., Wu, B., Yang, G.-H., Ji, Y., & Fan, J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-05-04
- Volume
- 59
- Issue
- 7
- Pages
- 953-962
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2126697949
- Cited by
- 270
- References
- 39
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.